<DOC>
	<DOCNO>NCT01892163</DOCNO>
	<brief_summary>Multicentre randomize control trial evaluate whether 5 monthly fix dose 700 µg Dexamethasone Posterior Segment Drug Delivery System ( Ozurdex ) efficacious Optical coherence tomography ( OCT ) -guided PRN dose patient refractory diabetic macular edema .</brief_summary>
	<brief_title>Multicentre Randomised Clinical Trial Comparing Fixed vs Pro Nata ( PRN ) Dosing 700 μg Dexamethasone</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>1 . Subjects either sex age 18 year 2 . Diagnosis diabetes mellitus ( type 1 type 2 ) . 3 . Best correct visual acuity study eye ≥34 ≤73 ETDRS letter 1m baseline attributable diabetic macular edema ( DME ) 4 . On clinical exam baseline study eye , retinal thickening due diabetic macular oedema involve centre macula OCT central subfield &gt; 300 micron despite previous therapy . 5 . Media clarity , pupillary dilation , subject cooperation sufficient adequate fundus photograph . 6 . Ability return study visit 7 . Visual acuity fellow eye ≥ 2/60 8 . Ability give inform consent throughout duration study Main 1 . Macular ischaemia 2 . Macular oedema consider due cause diabetic macular oedema . 3 . Coexistent ocular disease 4 . An ocular condition present ( diabetes ) , opinion investigator , might affect macular oedema alter visual acuity course study . 5 . A substantial cataract , opinion investigator , likely decrease visual acuity 3 line .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Diabetic macular edema , Ozurdex</keyword>
</DOC>